Cue Biopharma, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Cue Biopharma, Inc. (CUE) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$10.43 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-14.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-05-14
- Cue Biopharma, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was -$10.43M.
- Cue Biopharma, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$4.02M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month |
|---|---|
| 2018-03-31 | -$10.43M 10-Q · filed 2018-05-14 |
| 2017-03-31 | -$4.02M 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |